These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
104 related articles for article (PubMed ID: 9468701)
1. Regulating the pharmaceutical industry. Having rationing rules for new pharmaceuticals but not other treatments is senseless. Towse A BMJ; 1998 Jan; 316(7126):227. PubMed ID: 9468701 [No Abstract] [Full Text] [Related]
2. How NICE may be outflanked. Ferner RE; McDowell SE BMJ; 2006 May; 332(7552):1268-71. PubMed ID: 16735342 [No Abstract] [Full Text] [Related]
3. Regulating the pharmaceutical industry. Authors seem to have misunderstood pharmaceutical price regulation scheme. Read P BMJ; 1998 Jan; 316(7126):226; author reply 228. PubMed ID: 9468700 [No Abstract] [Full Text] [Related]
4. Regulating the pharmaceutical industry. Regulation may no longer be necessary. Rowlatt P BMJ; 1998 Jan; 316(7126):227; author reply 228. PubMed ID: 9468702 [No Abstract] [Full Text] [Related]
5. Money or your life? The health-wealth trade-off in pharmaceutical regulation. Maynard A; Cookson R J Health Serv Res Policy; 2001 Jul; 6(3):186-9. PubMed ID: 11467277 [TBL] [Abstract][Full Text] [Related]
13. The pharmacoeconomics of spiralling cancer drug costs - is there a viable solution? Alifrangis C; Krell J; Stebbing J Eur J Cancer; 2011 Jun; 47(9):1285-6. PubMed ID: 21550231 [No Abstract] [Full Text] [Related]
14. Regulating the pharmaceutical industry. Australian scheme has disadvantages. Clear PR; Grobler M BMJ; 1998 Jan; 316(7126):227. PubMed ID: 9468703 [No Abstract] [Full Text] [Related]
15. Satisfaction guaranteed--"payment by results" for biologic agents. Garber AM; McClellan MB N Engl J Med; 2007 Oct; 357(16):1575-7. PubMed ID: 17942870 [No Abstract] [Full Text] [Related]
17. Time to fix the price fix. Earl-Slater A Health Serv J; 1997 Nov; 107(5578):22-3. PubMed ID: 10174008 [TBL] [Abstract][Full Text] [Related]
18. Regulating the pharmaceutical industry. Further controls would discourage companies from investing in research. Lance SP BMJ; 1998 Jan; 316(7126):227-8; author reply 228. PubMed ID: 9468704 [No Abstract] [Full Text] [Related]
19. Should NHS patients be allowed to pay extra for their care? Debate is essential, not futile. Thornton H BMJ; 2002 Jan; 324(7329):110. PubMed ID: 11808518 [No Abstract] [Full Text] [Related]
20. Pharma focus. Market traders. Lewis C Health Serv J; 2003 Nov; 113(5883):suppl 2-3. PubMed ID: 14671865 [No Abstract] [Full Text] [Related] [Next] [New Search]